- Hantavirus vaccine in 2026? 2¢2%
No hantavirus vaccine is positioned for approval or broad availability by the end of 2026. All active candidates remain in preclinical or very early clinical stages, with no advanced human efficacy trials underway. Recent mRNA platforms, including single-dose candidates tested in hamsters at UTMB and work by Moderna with Korea University, have shown strong protection in rodent models against strains like Andes virus, yet these have not entered Phase 1 human testing. Older DNA vaccine efforts have completed limited Phase 1 safety studies but lack large-scale efficacy data or regulatory advancement. The 2026 cruise-ship outbreak has heightened awareness and prompted some funding discussions, yet development timelines for new vaccines—especially against regionally variable hantaviruses—typically span multiple years absent an extraordinary acceleration program. Realistic shifts before year-end would require unprecedented regulatory fast-tracking or emergency authorization based on preliminary data, scenarios viewed as improbable given current pipelines and resource constraints.
Rules
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.